Abstract: ObjectiveClinical observation of nimotop combined with cerebroprotein hydrolysate injection in the treatment of vascular cognitive impairment no dementia (VCIND) Methods42 VCIND cases were divided into three groups, each with 14 casesGroup A taking oral nimotop 30mg, tid; Group B injecting cerebroprotein hydrolysate injection 90mg in 5％ glucose injection (or 0.9％ sodium chloride injection) 250 mL slow intravenous infusion qd; Group C injecting nimotop 30mg, tid combined with cerebroprotein hydrolysate injection 90 mg in 5％ glucose injection (or 0.9％ sodium chloride injection) 250 mL slow infusion qd. Duration of treatment was 14 days. Two weeks before and after treatment, the Chinese version of MoCA scale and MMSE changes were taken. The results were analyzed statistically. ResultsWithin two weeks, the Chinese version of MoCA scale score of the combined treatment group was significantly improved compared with other groups. The difference was statistically significant(P < 0.05). Monotherapy before and after treatment score was no significant improvement. The MMSE scores were not improved (P ＞ 0.05). ConclusionRating scale by MoCAnimotop combined by cerebroprotein hydrolysate injection in treatment of VCIND were significantly superior to nimotop alone and to Cerebroprotein hydrolysate injection.

Key words: VCIND, nimotop, cerebroprotein hydrolysate injection, MoCA scale of Chinese version, MMSE